Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology.

The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. 

In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

Immunovant

Arbutus Biopharma

RTW Investments

SoftBank Capital

Suvretta Capital Management

Viking Global Investors

Dainippon Sumitomo Pharma

Eventide

Fidelity

Fidelity Management and Research Company

Palantir Technologies

Patient Square Capital

SoftBank Vision Fund

Founders Fund

Dexcel Pharma

Novaquest Capital Management

QVT Financial

Roivant Sciences

Domain Not Resolving

DNSSEC

Person Schema

Cloudflare

Cloudflare Network Error Logging

YouTube

Amazon Virginia Region

Ruby on Rails Token

Envoy

Jetpack Site Accelerator

Sales and Support

Amy Mahery

Chief Executive Officer Proteovant, Vant Portfolio Operating Partner (Roivant Sciences)

Drew Fromkin

President and Chief Operating Officer

Eric Venker

General Counsel

Jo Chen

Chief Executive Officer

Matthew Gline

Chief Communications Officer

Paul Davis

Chief Accounting Officer

Rakhi Kumar

Finance and Administration

Richard Pulik

Executive Vice President, Head of Research and Development and Chief Medical Officer

Roger Sidhu

Board Members

Siulan Wang

Vivek Ramaswamy

Founder and Executive Chairman

Mayukh Sukhatme

Chief Investment Officer & President

Benjamin Zimmer

President, Roivant Health

Frank Torti

Vant Chair

Dan Rothman

Chief Information Officer

Celine Chan

Chief Information Security Officer

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.

Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.

New York Public Companies With Less Than $500M in Revenue

Health Care Companies With Less Than $1B in Revenue (Top 10K)

Biotechnology Companies With More Than $10M in Revenue

Investors Active in California (Top 10K)

Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates.

Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. Roivant does this by building Vants - nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying the technology. In addition to its biopharmaceutical subsidiaries, Roivant also builds technology-focused Vants focused on improving the process of developing and commercializing medicines.

Post-IPO Equity - Roivant Sciences

Private Equity Round - Roivant Sciences

Medical and Beauty Services and Agricultural Services

New York

United States

North America

Price Over Earnings Overview: Roivant Sciences

Bayer Asset Gives Roivant Sciences’ New ‘Vant’ a Shot at Besting a United Therapeutics Lung Drug

Roivant Sciences reports Q1 EPS 12c, consensus (26c)

Piper Sandler raises Roivant Sciences shares target on promising drug trial

Evaluating Roivant Sciences: Insights From 6 Financial Analysts

Roivant Sciences put volume heavy and directionally bearish

Roivant Sciences Gets RS Rating Upgrade

Goldman Sachs lifts Roivant Sciences stock target on study data

Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 400

Where Roivant Sciences Stands With Analysts

India

Asia

Canada

France

Europe

Switzerland

HTML5

GreenSock Animation Platform

Google Fonts

Amazon Route 53

Wordpress

Google Compute Engine

Modernizr

DigiCert

Microsoft Outlook

Office 365

Roivant Sciences owns Genevant

Espero Biopharma is a biotechnology company focused on developing therapies for neurological and endocrine diseases.

Espero Biopharma

Denovo Biopharma is a biotechnology company specializing in the research and development of treatments for neurological and endocrine diseases.

Denovo Biopharma

Kallyope is a biotechnology company that focuses on developing therapies for neurological and endocrine diseases.

Kallyope

Acellera is a technology company specializing in computable drug discovery for the pharmaceutical industry.

Acellera

Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company focused on the development and commercialization of medicines for inflammation and immunology areas. The company utilizes a model called Vants to develop and commercialize its medicines and technologies, with a focus on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

news impact assignment basic	general	Mar 8, 2024 1:10 AM	237e485d
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 1:10 AM	673ea826
company summary	general
signals	general	Mar 8, 2024 1:10 AM	155f5fee
crunchbase trigger	general	Oct 29, 2024 5:10 PM	43ac3887
crunchbase profile	general	Oct 30, 2024 5:55 AM	7bd27899
li profile	general	Mar 8, 2024 1:10 AM	a1ddc2c1
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	65748c84
peers	general	Mar 8, 2024 1:10 AM	9eff8644
news basic	general	Mar 8, 2024 1:10 AM	39a632b8
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ROIVANT

Roivant Sciences Ltd.

Last Close

11.49

21/11 21:00

Market Cap

8.31B

Beta: -

Volume Today

7.11M

Avg: -